Vasoactive Intestinal Peptide Induces Regulatory Dendritic Cells That Prevent Acute Graft-versus-host Disease While Maintaining the Graft-versus-tumor Response

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2006 Jan 19

PMID 16418327

Citations 35

Authors

Alejo Chorny

Elena Gonzalez-Rey

Amelia Fernandez-Martin

Doina Ganea

Mario Delgado

Affiliations

Soon will be listed here.

Abstract

Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation (BMT) for the treatment of leukemia and other immunogenetic disorders. The use of tolerogenic dendritic cells (DCs) that induce the generation/activation of regulatory T (Tr) cells for the treatment of acute GVHD following allogeneic BMT has been recently established. Therefore, the identification of factors that contribute to the development of tolerogenic DCs is highly relevant. We report on the use of the known immunosuppressive neuropeptide, the vasoactive intestinal peptide (VIP), as a new approach to induce tolerogenic DCs with the capacity to prevent acute GVHD. DCs differentiated in the presence of VIP impair allogeneic haplotype-specific responses of donor CD4(+) cells in mice given transplants by inducing the generation of Tr cells in the graft. VIP-induced tolerogenic DCs did not abrogate the graft-versus-leukemia response presumably by not affecting the cytotoxicity of transplanted T cells against the leukemic cells. Therefore, the inclusion of VIP-induced tolerogenic DCs in future therapeutic regimens may minimize the dependence on nonspecific immunosuppressive drugs used currently as antirejection therapy, and facilitate the successful transplantation from mismatched donors, by reducing the deleterious consequences of acute GVHD and extending the applicability of BMT.

Citing Articles

Generation of Human Regulatory Dendritic Cells from Cryopreserved Healthy Donor Cells and Hematopoietic Stem Cell Transplant Recipients.

Scroggins S, Schlueter A Cells. 2023; 12(19).

PMID: 37830587 PMC: 10571850. DOI: 10.3390/cells12192372.

Cellular Immunotherapy in Mice Prevents Maternal Hypertension and Restores Anti-Inflammatory Cytokine Balance in Maternal and Fetal Tissues.

Gray G, Scroggins D, Wilson K, Scroggins S Int J Mol Sci. 2023; 24(17).

PMID: 37686399 PMC: 10487605. DOI: 10.3390/ijms241713594.

Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.

Ravindranathan S, Passang T, Li J, Wang S, Dhamsania R, Ware M Nat Commun. 2022; 13(1):6418.

PMID: 36302761 PMC: 9613684. DOI: 10.1038/s41467-022-34242-4.

Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression.

Zhu J, Wang Y, Li J, Das P, Zhang H, Passang T Blood. 2022; 140(12):1431-1447.

PMID: 35443019 PMC: 9507007. DOI: 10.1182/blood.2021012561.

Generation of Powerful Human Tolerogenic Dendritic Cells by Lentiviral-Mediated IL-10 Gene Transfer.

Comi M, Amodio G, Passeri L, Fortunato M, Santoni de Sio F, Andolfi G Front Immunol. 2020; 11:1260.

PMID: 32695103 PMC: 7338371. DOI: 10.3389/fimmu.2020.01260.

References

Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T . Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity. 2003; 18(3):367-79. DOI: 10.1016/s1074-7613(03)00055-4. View

Steinman R, Hawiger D, Nussenzweig M . Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685-711. DOI: 10.1146/annurev.immunol.21.120601.141040. View

Jones S, Murphy G, Korngold R . Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003; 9(4):243-56. DOI: 10.1053/bbmt.2003.50027. View

Wakkach A, Fournier N, Brun V, Breittmayer J, Cottrez F, Groux H . Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003; 18(5):605-17. DOI: 10.1016/s1074-7613(03)00113-4. View

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman C, Strober S . CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003; 9(9):1144-50. DOI: 10.1038/nm915. View

Morelli A, Thomson A . Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev. 2003; 196:125-46. DOI: 10.1046/j.1600-065x.2003.00079.x. View

Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon B . Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003; 112(11):1688-96. PMC: 281639. DOI: 10.1172/JCI17702. View

Hackstein H, Thomson A . Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol. 2004; 4(1):24-34. DOI: 10.1038/nri1256. View

Zhang Y, Joe G, Zhu J, Carroll R, Levine B, Hexner E . Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood. 2004; 103(10):3970-8. DOI: 10.1182/blood-2003-09-3135. View

10.

Delgado M, Pozo D, Ganea D . The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004; 56(2):249-90. DOI: 10.1124/pr.56.2.7. View

11.

Rutella S, Lemoli R . Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol Lett. 2004; 94(1-2):11-26. DOI: 10.1016/j.imlet.2004.04.015. View

12.

Pozo D, Delgado M . The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. FASEB J. 2004; 18(12):1325-34. DOI: 10.1096/fj.03-1440hyp. View

13.

Wagner J, Donnenberg A, Noga S, Cremo C, Gao I, Yin H . Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood. 1988; 72(4):1168-76. View

14.

Drobyski W, Majewski D . Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex.... Blood. 1996; 87(12):5355-69. View

15.

Thornton A, Shevach E . CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998; 188(2):287-96. PMC: 2212461. DOI: 10.1084/jem.188.2.287. View

16.

Cooke K, Krenger W, Hill G, Martin T, Kobzik L, Brewer J . Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood. 1998; 92(7):2571-80. View

17.

Herrera C, Torres A, Garcia-Castellano J, Roman J, Martin C, Serrano J . Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Bone Marrow Transplant. 1999; 23(5):443-50. DOI: 10.1038/sj.bmt.1701493. View

18.

Gregg R, Jain R, Schoenleber S, Divekar R, Jeremiah Bell J, Lee H . A sudden decline in active membrane-bound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol. 2004; 173(12):7308-16. DOI: 10.4049/jimmunol.173.12.7308. View

19.

Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M . Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci U S A. 2005; 102(38):13562-7. PMC: 1224633. DOI: 10.1073/pnas.0504484102. View

20.

Delgado M, Gonzalez-Rey E, Ganea D . The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol. 2005; 175(11):7311-24. DOI: 10.4049/jimmunol.175.11.7311. View